SYRE Company Profile and Key Details

NASDAQ : SYRE

Spyre Therapeutics

$30.61

0.47+1.56%

At Close 4:00 PM

69.16

ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Spyre Therapeutics, Inc. (SYRE) stock surged +1.56%, trading at $30.61 on NASDAQ, up from the previous close of $30.14. The stock opened at $30.46, fluctuating between $30.46 and $31.45 in the recent session.

Stock Snapshot

30.14

Prev. Close

1.85B

Market Cap

30.46

Day Low

-23.19

P/E Ratio

-1.32

EPS (TTM)

N/A

Cash Flow per Share

30.46

Open

60.4M

Number of Shares

31.45

Day High

77.38%

Free Float in %

N/A

Book Value

456.08K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jan 09, 2026	30.46	31.45	30.36	30.61	455.73K
Jan 08, 2026	30.42	30.71	29.60	30.14	569.28K
Jan 07, 2026	30.45	31.69	30.21	31.05	588.67K
Jan 06, 2026	29.92	30.39	29.43	30.33	752.16K
Jan 05, 2026	30.49	30.55	28.00	29.96	986.67K
Jan 02, 2026	32.76	33.31	30.11	30.58	888.69K
Dec 31, 2025	31.78	32.84	31.52	32.76	533.17K
Dec 30, 2025	32.45	32.53	31.50	31.88	392.86K
Dec 29, 2025	32.77	33.22	32.05	32.56	342.79K
Dec 26, 2025	33.00	33.03	32.30	32.94	304.18K
Dec 24, 2025	33.38	34.10	32.79	33.05	291.95K
Dec 23, 2025	33.84	34.44	32.96	33.23	518.24K
Dec 22, 2025	32.93	34.52	32.50	34.20	1.18M
Dec 19, 2025	33.82	34.84	33.22	33.40	3.64M
Dec 17, 2025	33.51	34.32	32.76	33.06	479.25K
Dec 16, 2025	33.00	33.52	32.26	32.97	518.71K
Dec 15, 2025	33.93	34.96	33.15	33.34	729.06K
Dec 12, 2025	34.36	35.17	33.24	33.62	724.27K
Dec 11, 2025	34.77	35.31	34.17	34.36	666.85K
Dec 10, 2025	33.70	34.94	33.51	34.66	696.08K

Contact Details

Waltham, MA 02453

United States

https://www.spyre.com 617 651 5940

About Company

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4�7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4�7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4�7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Stock Peers

REGN

-4.46-0.56%

Regeneron Pharmaceuticals, Inc.$796.55 ARGX

-7.07997-0.89%

argenx SE$788.49 MDGL

-42.16-7.58%

Madrigal Pharmaceuticals, Inc.$514.06 UTHR

-7.6-1.55%

United Therapeutics Corporation$483.23 VRTX

-5.82-1.24%

Vertex Pharmaceuticals Incorporated$463.86 ALNY

-1.11-0.28%

Alnylam Pharmaceuticals, Inc.$398.29 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-5.93-2.01%

Praxis Precision Medicines, Inc.$288.45 KRYS

12.5+5.02%

Krystal Biotech, Inc.$261.41 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Spyre Therapeutics, Inc. (NASDAQ:SYRE) closed at $30.61 USD, gaining $0.47 (1.56%) from the previous close of $30.14. The stock is currently mid-range between its 52-week high and low $10.91 and $35.31. With a market capitalization of about $1.85 billion, Spyre Therapeutics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~3.18). Key stats such as the average daily volume over the past year has been around 907.42 thousand shares, volume is running light vs its 52-week average. Headquartered in Waltham, MA, Spyre Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Cameron Turtle, the company employs approximately 73 people and listed since April 07, 2016. Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD).

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 -5.45%, SMA50 5.9%, SMA200 57.59%). The stock’s 14-day RSI is 47.89 (neutral), while the ATR of 1.59 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -13.31% below its high and over 180.57% above its low. Average 10-day trading volume of 706.87 thousand shares is below the 3-month average of 896.23 thousand, indicating normal recent market interest.

Valuation Metrics

Spyre Therapeutics, Inc. trades at a P/E ratio of -15.4, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 5.04 trading at moderately above to book value. The P/FCF stands at -11.42, also below market averages.

Dividend & Fair Value

Spyre Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.90. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Spyre Therapeutics, Inc. generated EPS of -$2.18 over the past year. Five-year average earnings growth is 44.65%. Wall Street analysts project EPS growth of -0.65% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $70.00 to $43.00. The high target offers 128.68% upside. The low target suggests 40.48% downside. The mean target is $56.50. This offers 84.58% upside. Spyre Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 04, 2025, missed forecasts by -77.94%. The prior quarter beat by -32.88%. Over the last six quarters, Apple has recorded several small beats. These include -4.44% in August 07, 2024.

Shareholding & Insider Activity

Spyre Therapeutics, Inc. has 60.40 million shares outstanding. The public float is 46.75 million shares, elevated short interest at 28.03% of float. This equals 13.19 million shares. The short ratio is 25.91 days. Institutional investors hold 90.45% of the float. Insiders own 6.7%. Turtle Cameron holds 671.91 thousand shares, Burrows Scott L has 97.99 thousand shares and Albers Jeffrey W. has 27.36 thousand shares. Over the past six months, insider transactions show net selling. They sold 39.38 thousand shares across 4 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Spyre Therapeutics has not generated any revenue.
On valuation metrics, Spyre Therapeutics trades at a P/E of -15.40, P/S of 0.00 and P/B of 5.04. The current ratio is 10.90 and quick ratio is 10.90. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -60.15 days , indicating it collects cash faster than it pays suppliers.

Price Forecast & Outlook

Our AI price prediction model suggests that Spyre Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.47%, with price expected at $28.63 by January 23, 2026, within a range of $27.19 to $30.12 3-Month Outlook: Projected rise of 49.66%, reaching $45.81 by April 09, 2026, with a range of $44.81 to $47.44. 1-Year Outlook: Projected gain of 12.94%, with price at $34.57 by December 31, 2026, within a range of $31.40 to $38.09.

Key Takeaways

Spyre Therapeutics, Inc. (NASDAQ:SYRE) shares are flat -8.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Spyre Therapeutics, Inc. trading at a premium to the broader market with a P/E of -15.4. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $57.71, suggesting 88.53% upside. Our AI forecast model points to short-term weakness (-6.47% over two weeks), a medium-term rise (49.66% over three months), and a longer-term gain (12.94% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Spyre Therapeutics, Inc. (SYRE) stock price?

Spyre Therapeutics, Inc. (NASDAQ: SYRE) stock price is $30.61 in the last trading session. During the trading session, SYRE stock reached the peak price of $31.45 while $30.46 was the lowest point it dropped to. The percentage change in SYRE stock occurred in the recent session was 1.56% while the dollar amount for the price change in SYRE stock was $0.47.

SYRE's industry and sector of operation?

The NASDAQ listed SYRE is part of Biotechnology industry that operates in the broader Healthcare sector. Spyre Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of SYRE?

No Data

How SYRE did perform over past 52-week?

SYRE's closing price is 180.57% higher than its 52-week low of $10.91 where as its distance from 52-week high of $35.31 is -13.31%.

How many employees does SYRE have?

Number of SYRE employees currently stands at 73.

Link for SYRE official website?

Official Website of SYRE is: https://www.spyre.com

How do I contact SYRE?

SYRE could be contacted at phone 617 651 5940 and can also be accessed through its website. SYRE operates from 221 Crescent Street, Waltham, MA 02453, United States.

How many shares of SYRE are traded daily?

SYRE stock volume for the day was 456.08K shares. The average number of SYRE shares traded daily for last 3 months was 907.43K.

What is the market cap of SYRE currently?

The market value of SYRE currently stands at $1.85B with its latest stock price at $30.61 and 60.4M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	73
Beta	3.18
Sales or Revenue	N/A
5Y Sales Change%	-0.974%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

SYRE Company Profile and Key Details

Spyre Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Earnings & Analyst Outlook

Company Overview

Dividend & Fair Value

Financial & Profitability Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways